Minerva Neurosciences (NERV) Getting Somewhat Positive Media Coverage, Study Finds
News stories about Minerva Neurosciences (NASDAQ:NERV) have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Minerva Neurosciences earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 47.6591567089451 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Minerva Neurosciences (NASDAQ NERV) remained flat at $$5.20 during midday trading on Friday. The stock had a trading volume of 87,342 shares, compared to its average volume of 180,996. Minerva Neurosciences has a 52 week low of $4.80 and a 52 week high of $14.15.
Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter. During the same period in the previous year, the firm earned ($0.24) earnings per share. analysts anticipate that Minerva Neurosciences will post -1.28 earnings per share for the current fiscal year.
Several equities analysts have issued reports on the company. Zacks Investment Research lowered Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Friday, August 25th. BidaskClub lowered Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Finally, Citigroup Inc. assumed coverage on Minerva Neurosciences in a report on Friday, September 1st. They set a “buy” rating and a $11.00 price target on the stock. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $13.94.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Stock Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related stocks with our FREE daily email newsletter.